Levi Makala

Georgia Regents Medical Center

Papers

1

Total Citations

27

H-Index

1

About

Levi Makala is a pioneering researcher in hematology and molecular therapeutics, whose work centers on developing novel treatments for β-hemoglobinopathies such as sickle cell disease and β-thalassemia. His key research areas include fetal globin gene reactivation, high-throughput drug screening, and in vivo preclinical models. Makala’s major contribution lies in identifying and validating small-molecule inducers of fetal (γ) globin expression—a clinically validated strategy to ameliorate disease severity. His landmark 2015 study, cited 27 times, demonstrated that compounds discovered through a high-throughput LCR-γ-globin-GFP reporter assay were active in anemic baboons and transgenic mice, offering a promising path toward safe, orally bioavailable therapies. This work bridges the gap between bench-based drug discovery and translational efficacy, showcasing his ability to move from robotic screening to complex primate models. Makala’s impact is further underscored by his focus on addressing critical unmet needs in hemoglobinopathies, where current options remain limited. His achievements highlight a commitment to rigorous, translatable science, making him a notable figure in the quest for accessible treatments for millions of patients worldwide.

Research Focus

Key Achievements

1
H-Index
1
Papers
27
Total Citations
27
Avg Citations/Paper
🏆 Most Cited Paper
Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice
27 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Georgia Regents Medical Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago